5-Fluorouracil, 99%
5-Fluorouracil, 99%
5-Fluorouracil, 99%

5-Fluorouracil, 99%

5-Fluorouracil, CAS # 51-21-8, is an analogue base composed of uracil with a position 5 hydrogen fluorine substitution. | CAS: 51-21-8 | C4H3FN2O2 | 130.08 g/mol
Have Questions?
Change viewbuttonViewtableView
Quantity:
100 g
1 g
5 g
25 g
Packaging:
Glass bottle
Catalog number FSA228441000
View Price:Sign in to see your account pricing. Need an account? Register with us today.
Quantity:
100 g
Packaging:
Glass bottle
Request bulk or custom format
Specifications
Chemical Name or Material5-Fluorouracil
CAS51-21-8
Health Hazard 1GHS Signal Word: Danger
Health Hazard 2GHS H Statement
Suspected of causing genetic defects.
Suspected of damaging the unborn child.
Toxic if swallowed.
Harmful in contact with skin.
Harmful if inhaled.
Causes serious eye irritation.
Causes skin irri
Health Hazard 3GHS P Statement
Wear protective gloves/protective clothing/eye protection/face protection.
IF SWALLOWED: Immediately call a POISON CENTER or doctor/physician.
IF INHALED: Remove victim to fresh air and keep at rest in a position comforta
View more
This Thermo Scientific Chemicals brand product was originally part of the Acros Organics product portfolio. Some documentation and label information may refer to the legacy brand. The original Acros Organics product / item code or SKU reference has not changed as a part of the brand transition to Thermo Scientific Chemicals.

General Description

• 5-Fluorouracil is an antimetabolite and antineoplastic that prevents DNA synthesis by blocking conversion of deoxyuridylic acid

• 5-Fluorouracil can replace uracil in RNA and prevent protein synthesis and cell growth

Applications

• 5-Fluorouracil can be used for laboratory research on tumor growth and immunosuppression

• 5-Fluorouracil may also be appropriate for laboratory studies of neurotoxicity, cell lysis, and DNA damage

RUO – Research Use Only

General References:

  1. Kato, K.; Shah, M.A.; Enzinger, P.; Bennouna, J.; Shen, L.; Adenis, A.; Sun, J.M.; Cho, B.C.; Özgüroğlu, M.; Kojima, T.; Kostorov, V.; Hierro, C.; Zhu, Y.; McLean, L.A.; Shah, S.; Doi, T. KEYNOTE-590: Phase III study of first-line chemotherapy with or without pembrolizumab for advanced esophageal cancer. Future Oncol. 2019, (10), 1057-1066.
  2. Wagner, A.D.; Syn, N.L.; Moehler, M.; Grothe, W.; Yong, W.P.; Tai, B.C.; Ho, J. Unverzagt S. Chemotherapy for advanced gastric cancer. Cochrane Database Syst Rev. 2017, 8(8), CD004064.